Clear Street last night initiated coverage of Akero Therapeutics (AKRO) with a Buy rating and $49 price target The company’s sole clinical asset and FGF21R agonist, Efruxifermin, demonstrates “best-in-class potential” for metabolic dysfunction-associated steatohepatitis treatment with a high probability of success in ongoing Phase 3 studies, the analyst tells investors in a research note. The firm says Efruxifermin’s “superior efficacy” versus competitors in the F4 cirrhosis market “establishes clear differentiation.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics initiated with a Buy at Clear Street
- Akero Therapeutics: Strong Financials and Promising Clinical Progress Justify Buy Rating
- Promising Developments and Strong Financial Position Support Buy Rating for Akero Therapeutics
- Akero Therapeutics price target raised to $75 from $72 at H.C. Wainwright
- Akero Therapeutics price target lowered to $90 from $96 at Morgan Stanley
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue